82 180

Cited 0 times in

Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline

Authors
Min, KJ | Kwon, SH | Kim, K | Kim, S | Kim, HJ | Seong, SJ | Song, YJ | Lee, KH | Lee, SW | Lee, JW | Chang, SJ  | Ju, W | Kim, YT | Lee, JK
Citation
Journal of gynecologic oncology, 30(2). : e31-e31, 2019
Journal Title
Journal of gynecologic oncology
ISSN
2005-03802005-0399
Abstract
In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.
Keywords
MeSH

DOI
10.3802/jgo.2019.30.e31
PMID
30740959
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Ajou Authors
장, 석준
Full Text Link
Files in This Item:
30740959.pdfDownload
Export

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse